EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification and characterisation of calcitonin receptor isoforms expressed in glioblastoma derived glioma stem and U‐87 MG cells

Pragya Gupta, Sebastian Gb Furness, Tahereh Gharbi, Ric De Paoli-Iseppi, Shweta S Joshi, Michael Clark, David L Hare, Peter Wookey iD

FEBS Open Bio · 13.08.2026

DOI: 10.1002/2211-5463.70322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 13.08.2026. Verfasst von Pragya Gupta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Austin Health, Heidelberg), University of Melbourne, Heidelberg, Australia. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council, University of Melbourne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a highly lethal brain cancer in which the calcitonin receptor (CT Receptor), encoded by the CALCR gene, is expressed in 78–88% of patient biopsies. Here, we investigate whether the CT Receptor plays a role in cancer cell survival. In cancer cell lines, knockdown of CALCR disrupts the cell cycle and induces apoptosis, supporting an essential pro‐survival role. The CALCR gene produces three main transcripts in humans, of which Transcript 1 encodes CALCR b mRNA including exon 10 and is translated into the CT b Receptor isoform, and Transcripts 2 and 3 which are translated into the CT a Receptor. CALCR b expression is conserved across a diverse range of mammalian species. We examined the expression of all CT Receptor isoforms ( CALCR total ) and CALCR b expression in four high‐grade glioma stem‐like cell lines and in U‐87 MG glioblastoma cells. Using qPCR, we observed stable levels of both CALCR total and CALCR b expression under conditions of autophagy or apoptosis, consistent with a requirement for CALCR b in cell survival. As alternative splicing (AS) of key genes in cancers confers tumour resilience, we investigated AS of CALCR transcript 2 using long‐read nanopore sequencing. Unexpectedly, we discovered a novel AS event causing inclusion of exon 10 within Transcript 2 in all glioblastoma cell lines investigated. This finding, together with stable CALCR b expression under cellular stress and the finding by other groups confirming that knockdown of CT Receptor compromises cell survival, implicates the CT b Receptor as a potential oncoprotein.

Schlagwörter

Stichwörter der Autor:innen

CTb Receptor isoformalternative splicingapoptosisautophagycalcitonin receptorglioblastomananopore sequencing

Autor:innen und Institutionen

  • Department of Medicine (Austin Health, Heidelberg), University of Melbourne, Heidelberg, Australia.
  • School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia, Australia.
  • Department of Anatomy and Physiology, University of Melbourne, Parkville, Australia.

ORCID-Profile: Peter Wookey

Förderung

  • Australian Research Council
  • University of Melbourne

Zitieren

APA

Gupta, P., Furness, S. G., Gharbi, T., De Paoli-Iseppi, R., Joshi, S. S., Clark, M., Hare, D. L., & Wookey, P. (2026). Identification and characterisation of calcitonin receptor isoforms expressed in glioblastoma derived glioma stem and U‐87 MG cells. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70322

Vancouver

Gupta P, Furness SG, Gharbi T, De Paoli-Iseppi R, Joshi SS, Clark M, et al. Identification and characterisation of calcitonin receptor isoforms expressed in glioblastoma derived glioma stem and U‐87 MG cells. FEBS Open Bio. 2026. doi:10.1002/2211-5463.70322

BibTeX
@article{Gupta2026,
  author = {Gupta, Pragya and Furness, Sebastian Gb and Gharbi, Tahereh and De Paoli-Iseppi, Ric and Joshi, Shweta S and Clark, Michael and Hare, David L and Wookey, Peter},
  title = {Identification and characterisation of calcitonin receptor isoforms expressed in glioblastoma derived glioma stem and U‐87 MG cells},
  journal = {FEBS Open Bio},
  year = {2026},
  doi = {10.1002/2211-5463.70322}
}
Kostenlos starten →